Delavirdine
- 1 January 2001
- journal article
- review article
- Published by Springer Nature in Clinical Pharmacokinetics
- Vol. 40  (3) , 207-226
- https://doi.org/10.2165/00003088-200140030-00005
Abstract
Delavirdine, a non-nucleoside reverse transcriptase inhibitor (NNRTI), is a potent and specific inhibitor of HIV-1 reverse transcriptase. The approved therapeutic regimen for delavirdine is 400mg 3...Keywords
This publication has 52 references indexed in Scilit:
- Randomized Study of Saquinavir with Ritonavir or Nelfinavir Together with Delavirdine, Adefovir, or Both in Human Immunodeficiency Virus–Infected Adults with Virologic Failure on Indinavir: AIDS Clinical Trials Group Study 359The Journal of Infectious Diseases, 2000
- Initial Therapy with Protease Inhibitor-Sparing Regimens: Evaluation of Nevirapine and DelavirdineClinical Infectious Diseases, 2000
- Effects of the Antifungal Agents on Oxidative Drug MetabolismClinical Pharmacokinetics, 2000
- IndinavirDrugs, 1999
- Protease Inhibitors as Inhibitors of Human Cytochromes P450: High Risk Associated with RitonavirThe Journal of Clinical Pharmacology, 1998
- RitonavirClinical Pharmacokinetics, 1998
- SaquinavirClinical Pharmacokinetics, 1998
- EfavirenzDrugs, 1998
- In vitro protein-binding characteristics of delavirdine and its N-dealkylated metaboliteAntiviral Research, 1996
- Clinical Pharmacokinetics of ZidovudineClinical Pharmacokinetics, 1996